RP6530

DRUG3 trials

Sponsors

Rhizen Pharmaceuticals SA

Conditions

HealthyLymphoma, B-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralT-Cell Lymphoma

Phase 1

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies

CompletedNCT02017613

Rhizen Pharmaceuticals SALymphoma, B-Cell, T-Cell Lymphoma

Start: 2013-11-30End: 2016-05-31Updated: 2016-06-24

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

CompletedNCT02567656

Rhizen Pharmaceuticals SALymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Start: 2015-09-30End: 2018-12-10Updated: 2020-01-13

To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers

CompletedNCT02690727

Rhizen Pharmaceuticals SAHealthy

Start: 2016-02-29End: 2016-03-31Updated: 2017-11-28

Related Papers

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Blood2019-11-133 citations

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood2018-11-2910 citations

Tenalisib, a dual PI3K δ/γ inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma.

Journal of Clinical Oncology2018-05-2010 citations

Safety and Anti-Tumour Activity of RP6530, Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study

Blood2017-12-073 citations

SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI‐CENTER STUDY

Hematological Oncology2017-06-016 citations

DUAL PI3K δ/γ INHIBITOR RP6530 IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL LYMPHOMA: DOSE ESCALATION FINDINGS.

Hematological Oncology2017-06-011 citations

A Dose Escalation Study of RP6530, a Novel Dual PI3K δ/γ Inhibitor, in Patients with Relapsed/Refractory T-Cell Lymphoma

Blood2016-12-024 citations

Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study

Blood2016-12-024 citations

A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood2015-12-033 citations

A Phase I Dose Escalation Study of RP6530, a Novel, Dual PI3K-γδ Inhibitor, for Patients with Relapsed or Refractory Hematologic Malignancies

Blood2014-12-066 citations